Payment overview · 2025
General Payments
$1,417.02
41 reported records · 16 companies
Healthcare provider profile · identity verified
Mark Elliot Wagner, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · READING, PA · NPI 1033202502
Verified facts
What the public records show
CMS Open Payments records show Mark Elliot Wagner, D.O. received $1,417.02 in general payments during 2025 across 41 reported records.
Novo Nordisk Inc accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 598 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $295.04 | 20.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $254.92 | 18.0% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $229.48 | 16.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.72 | 10.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $94.64 | 6.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.58 | 5.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.52 | 4.7% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $59.15 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.16 | 2.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.91 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.31 | 2.0% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $26.46 | 1.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.21 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.72 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.67 | 1.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.53 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,364.52 | 39 |
| Education | $52.50 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $271.12 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $249.20 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.92 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $94.64 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.58 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.58 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $75.54 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $72.21 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.52 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $59.15 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.16 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.16 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.INSTILL Normalized: v a c instill |
Device | Solventum Corporation | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE TRIVALENT Normalized: fluzone trivalent |
Biological | SANOFI PASTEUR INC. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 51 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
105 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
51 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
598 | 84 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 901 | 178 |
| Furosemide | Furosemide | 765 | 132 |
| Gabapentin | Gabapentin | 700 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 693 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 640 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 610 | 108 |
| Eliquis | Apixaban | 598 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 448 | 107 |
| Lisinopril | Lisinopril | 387 | 82 |
| Potassium Chloride | Potassium Chloride | 387 | 71 |
| Losartan Potassium | Losartan Potassium | 338 | 67 |
| Metformin Hcl | Metformin Hcl | 334 | 73 |
| Sertraline Hcl | Sertraline Hcl | 306 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 258 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 245 | 46 |
| Simvastatin | Simvastatin | 224 | 48 |
| Allopurinol | Allopurinol | 201 | 34 |
| Tramadol Hcl | Tramadol Hcl | 197 | 41 |
| Prednisone | Prednisone | 196 | 86 |
| Mirtazapine | Mirtazapine | 189 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 36 |
| Carvedilol | Carvedilol | 177 | 29 |
| Xarelto | Rivaroxaban | 172 | 22 |
| Warfarin Sodium | Warfarin Sodium | 169 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 168 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 34 |
| Trazodone Hcl | Trazodone Hcl | 166 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 164 | 26 |
| Latanoprost | Latanoprost | 143 | 25 |
| Glimepiride | Glimepiride | 142 | 33 |
| Montelukast Sodium | Montelukast Sodium | 141 | 24 |
| Donepezil Hcl | Donepezil Hcl | 136 | 24 |
| Buspirone Hcl | Buspirone Hcl | 128 | 30 |
| Alprazolam | Alprazolam | 127 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 23 |
| Omeprazole | Omeprazole | 125 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 36 |
| Levetiracetam | Levetiracetam | 116 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 30 |
| Januvia | Sitagliptin Phosphate | 115 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 106 | 21 |
| Lorazepam | Lorazepam | 105 | 45 |
| Myrbetriq | Mirabegron | 105 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 20 |
| Finasteride | Finasteride | 93 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 24 |
| Spironolactone | Spironolactone | 85 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 19 |
| Meloxicam | Meloxicam | 79 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 13 |
| Entresto | Sacubitril/Valsartan | 72 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 51 |
| Famotidine | Famotidine | 69 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 68 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 18 |
| Lovastatin | Lovastatin | 67 | 11 |
| Torsemide | Torsemide | 65 | 16 |
| Farxiga | Dapagliflozin Propanediol | 63 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 14 |
| Novolog Flexpen | Insulin Aspart | 62 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 15 |
| Risperidone | Risperidone | 60 | suppressed |
| Bumetanide | Bumetanide | 58 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 57 | 15 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 57 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 56 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 55 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 55 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 11 |
| Pregabalin | Pregabalin | 54 | 15 |
| Memantine Hcl | Memantine Hcl | 53 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 51 | 46 |
| Metformin Hcl Er | Metformin Hcl | 51 | 12 |
| Olanzapine | Olanzapine | 51 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 47 | 15 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Tradjenta | Linagliptin | 46 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 46 | suppressed |
| Digoxin | Digoxin | 45 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Levemir Flexpen | Insulin Detemir | 44 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 31 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 43 | suppressed |
| Cephalexin | Cephalexin | 42 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | 12 |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 37 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 37 | 18 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 19 |
| Atenolol | Atenolol | 36 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 11 |
| Oxycontin | Oxycodone Hcl | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 35 | 11 |
| Baclofen | Baclofen | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 29 |
| Temazepam | Temazepam | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Insulin Lispro | Insulin Lispro | 31 | suppressed |
| Jantoven | Warfarin Sodium | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 11 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Haloperidol | Haloperidol | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 16 |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 22 | 20 |
| Topiramate | Topiramate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 15 |
| Amiloride Hcl | Amiloride Hcl | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Procrit | Epoetin Alfa | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Acetylcysteine | Acetylcysteine | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Exelon | Rivastigmine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,417.02 · 41 records | Novo Nordisk Inc | ABRYSVO, AFREZZA, AIRSUPRA, AREXVY, BEYFORTUS, BREZTRI, COMIRNATY, CONTRAVE, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE TRIVALENT, JARDIANCE, LEQVIO, MENQUADFI, MOUNJARO, NURTEC ODT, Ozempic, PREVENA, PREVNAR 20, QULIPTA, REXULTI, SHINGRIX, UBRELVY, V.A.C.INSTILL, Veozah, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error